Korea Investment CORP Purchases 34,419 Shares of Insulet Corporation $PODD

Korea Investment CORP increased its position in shares of Insulet Corporation (NASDAQ:PODD) by 91.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 71,990 shares of the medical instruments supplier’s stock after buying an additional 34,419 shares during the period. Korea Investment CORP owned 0.10% of Insulet worth $22,618,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. Cetera Investment Advisers raised its position in shares of Insulet by 167.0% in the 1st quarter. Cetera Investment Advisers now owns 6,455 shares of the medical instruments supplier’s stock worth $1,695,000 after acquiring an additional 4,037 shares in the last quarter. Mackenzie Financial Corp grew its stake in Insulet by 39.9% during the first quarter. Mackenzie Financial Corp now owns 10,576 shares of the medical instruments supplier’s stock worth $2,777,000 after purchasing an additional 3,015 shares during the period. Bayforest Capital Ltd increased its holdings in Insulet by 106.8% in the first quarter. Bayforest Capital Ltd now owns 608 shares of the medical instruments supplier’s stock worth $160,000 after purchasing an additional 314 shares in the last quarter. Natixis Advisors LLC lifted its stake in Insulet by 33.9% in the first quarter. Natixis Advisors LLC now owns 59,412 shares of the medical instruments supplier’s stock valued at $15,602,000 after buying an additional 15,041 shares during the period. Finally, Alberta Investment Management Corp lifted its stake in Insulet by 144.1% in the first quarter. Alberta Investment Management Corp now owns 8,300 shares of the medical instruments supplier’s stock valued at $2,180,000 after buying an additional 4,900 shares during the period.

Insider Buying and Selling at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Insulet Trading Up 0.1%

PODD opened at $327.09 on Friday. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88. The firm has a market capitalization of $23.01 billion, a PE ratio of 99.42, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company’s 50-day moving average is $321.98 and its 200 day moving average is $316.37.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s revenue for the quarter was up 29.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on PODD. Truist Financial lifted their price objective on shares of Insulet from $390.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, November 21st. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Stifel Nicolaus started coverage on shares of Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective on the stock. Wolfe Research boosted their target price on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Rothschild & Co Redburn increased their price target on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $379.65.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.